Sanofi’s Amlitelimab delivers in Phase 3 trials, heads for global filings
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
VETMEDIN (pimobendan) chewable tablets and VETMEDIN solution (pimobendan oral solution) can delay the onset of congestive heart failure (CHF) in dogs
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
Subscribe To Our Newsletter & Stay Updated